Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma

NCT00934518 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Inadequate patient accrual

Conditions

Squamous Cell Cancer of the Head and Neck

Interventions

RADIATION: Radiation
DRUG: Cetuximab

Sponsor

Milton S. Hershey Medical Center